This is a European, multi-centre, prospective registry that aims to determine the safety and efficacy of transoral incisionless fundoplication, with or without concomitant hiatal hernia repair, for the treatment of patients with gastro-oesophageal reflux disease (GORD).
Study Type
OBSERVATIONAL
Enrollment
500
Transoral Incisionless Fundoplication (TIF): The TIF procedure is an endoscopic, minimally invasive intervention designed to reconstruct the gastro-oesophageal valve and restore its function as a reflux barrier, without external incisions. The procedure is performed transorally using the EsophyX device under general anaesthesia. The device enables the creation of a 270° to 300° esophagogastric fundoplication. Concomitant TIF (cTIF): The cTIF procedure combines a laparoscopic hiatal hernia repair with the TIF performed in the same session. Patients with a hiatal hernia greater than 2 cm undergo laparoscopic reduction and crural repair, followed immediately by the TIF procedure using the EsophyX device. This combined approach addresses both the anatomical defect of the hiatal hernia and the functional deficiency of the gastro-oesophageal valve.
Department of General Surgery, Medical University of Vienna
Vienna, Austria
Gemelli Isola
Rome, Italy
University Hospital for Digestive Surgery
Belgrade, Serbia
Intesto
Bern, Switzerland
Gastroesophageal reflux disease health-related quality of life questionnaire (GERD-HRQL)
Change in reflux-specific quality of life questionnaires (The GERD-HRQL used in the study is composed of 16 questions related to symptoms of heartburn, regurgitation, swallowing and overall satisfaction. Each question provides a scaled score between 0-5 (0=no symptoms, 5= Symptoms incapacitating to do daily activities) with a total score of 75.)
Time frame: 6-months, 1-year, 2-year, 3-years, 5-, years
Reflux symptom index (RSI)
Change in reflux-specific quality of life questionnaire (The RSI used in the study is composed of 9 questions related to atypical symptoms of reflux or 'LPR'. Each question provides a scaled score between 0-5 (0=no problems, 5=severe problems) with a total score of 45.)
Time frame: 6-months, 1-year, 2-years, 3-years, 5-years
Proton pump inhibitor and/or histamine-2 receptor antagonist use
Change in acid suppression use
Time frame: 6-months, 1-year, 2-years, 3-years, 5-years
Physiological reflux testing
Change in pH physiological testing
Time frame: up to 5-years
Procedural outcomes (technical success)
Defined as successful completion of all steps of the cTIF or TIF2.0 procedure in the same sitting
Time frame: 30-days
Procedural outcomes (duration)
Total length of the procedure in minutes
Time frame: 30-days
Procedural outcomes (length of hospital stay
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Memorial bahçelievler hospital
Istanbul, Turkey (Türkiye)
Cleveland Clinic
Abu Dhabi, United Arab Emirates
Cleveland Clinic London
London, United Kingdom
The time in days from procedure to discharge from hospital
Time frame: 30-days
Adverse events
Adverse events (AE) following TIF2.0 according to the AGREE classification
Time frame: up to 30-days
Adverse events of special interest
Subjective reporting of dysphagia, excessive belching or inability to belch, significant bloating and/or distension, and persistent nausea and vomiting.
Time frame: Up to 5-years
Need for revisional procedure
The need for repreat endoscopic or surgical intervention due to recurrence of symptoms, failure of procedure of adverse events
Time frame: Up to 5-years